DSGN · Design Therapeutics, Inc.
Design Therapeutics Inc (DSGN)
What's happening
- DSGN is down 3.51% today, trading at $10.72. — Live quote
- Volume today (19,719) is well below its 3-month average of 695,140. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.32 actual vs. $-0.35 estimated (+8.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $909.9M | $646.5M | $429.7M | $189.1M | $223.7M |
| P/E | -12.32 | -9.05 | -6.43 | -3.07 | -4.17 |
| Price/Book | 4.51 | 2.96 | 2.15 | 0.89 | 0.98 |
| ROE | -36.60% | -32.76% | -33.46% | -28.93% | -23.54% |
| ROA | -34.34% | -31.00% | -31.56% | -27.65% | -22.59% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +90.4%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 10-Q, filed 2026-08-03; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on DSGN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | $0 | — | — | — |
| Operating income | -$22.2M | -$19.7M | -$19.3M | -$21.6M | -$20.4M | -$16.2M | -$15.0M | -$14.4M |
| Net income | -$20.2M | -$17.6M | -$17.0M | -$19.1M | -$17.7M | -$13.0M | -$11.8M | -$11.1M |
| EPS (diluted) | $-0.32 | $-0.29 | $-0.30 | $-0.34 | $-0.31 | $-0.23 | $-0.21 | $-0.20 |
| EPS (basic) | $-0.32 | $-0.29 | $-0.30 | $-0.34 | $-0.31 | $-0.23 | $-0.21 | $-0.20 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $215.1M | $230.4M | $226.2M | $211.8M | $222.9M | $237.5M | $252.1M | $261.6M |
| Total liabilities | $13.3M | $12.4M | $13.7M | $12.1M | $9.8M | $9.6M | $10.0M | $9.2M |
| Stockholders' equity | $201.9M | $218.1M | $212.5M | $199.7M | $213.0M | $227.9M | $242.1M | $252.5M |
| Total current assets | $212.0M | $227.0M | $223.8M | $209.0M | $219.8M | $233.6M | $248.0M | $257.2M |
| Total current liabilities | $11.2M | $10.2M | $13.1M | $11.2M | $8.7M | $8.2M | $8.5M | $7.4M |
| Cash & equivalents | $12.9M | $12.8M | $16.9M | $15.1M | $19.7M | $13.7M | $22.6M | $30.3M |
| Marketable securities (current) | $194.5M | $210.1M | $203.0M | $190.9M | $196.6M | $216.0M | $222.9M | $223.7M |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $694.0K | $824.0K | $981.0K | $1.1M | $1.3M | $1.4M | $1.4M | $1.6M |
| Accounts payable | $3.1M | $2.3M | $2.3M | $1.9M | $1.0M | $3.2M | $2.2M | $1.5M |
| Accrued liabilities | $8.1M | $7.9M | $10.7M | $9.3M | $7.7M | $5.1M | $6.3M | $6.0M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained earnings | -$334.8M | -$314.6M | -$297.0M | -$281.0M | -$264.0M | -$244.9M | -$227.2M | -$213.6M |
| Accumulated other comprehensive income (loss) | -$771.0K | -$268.0K | $403.0K | $358.0K | $305.0K | $450.0K | $475.0K | $914.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.5M | -$16.4M | -$12.0M | -$11.2M | -$14.4M | -$16.8M | -$9.9M | -$9.5M |
| Investing cash flow | $15.1M | -$7.6M | -$11.6M | $6.5M | $20.1M | $7.9M | $1.8M | -$5.8M |
| Financing cash flow | $605.0K | $19.9M | $25.3M | $37.0K | $361.0K | $23.0K | $263.0K | $1.0K |
| Free cash flow | -$15.5M | -$16.4M | -$12.0M | -$11.2M | -$14.5M | -$16.9M | -$9.9M | -$9.5M |
| Capital expenditures | $21.0K | $0 | $34.0K | $0 | $87.0K | $72.0K | $0 | -$16.0K |
| Share-based compensation | $3.9M | $3.9M | $3.4M | $3.6M | $4.0M | $3.5M | $3.5M | $3.1M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Purchases of investments | $12.4M | $52.6M | $87.6M | $78.1M | $39.5M | $86.5M | $64.4M | $66.5M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Operating income | -$79.5M | -$62.4M | -$78.2M | -$67.6M | -$35.8M |
| Net income | -$69.8M | -$49.6M | -$66.9M | -$63.3M | -$35.5M |
| EPS (diluted) | $-1.22 | $-0.88 | $-1.19 | $-1.14 | $-0.77 |
| EPS (basic) | $-1.22 | $-0.88 | $-1.19 | $-1.14 | $-0.77 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $226.2M | $252.1M | $289.6M | $341.1M | $390.6M |
| Total liabilities | $13.7M | $10.0M | $12.0M | $13.8M | $8.4M |
| Stockholders' equity | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M |
| Total current assets | $223.8M | $248.0M | $284.6M | $335.1M | $385.4M |
| Total current liabilities | $13.1M | $8.5M | $9.6M | $10.8M | $5.3M |
| Cash & equivalents | $16.9M | $22.6M | $21.2M | $26.5M | $298.6M |
| Marketable securities (current) | $203.0M | $222.9M | $260.6M | $303.9M | $85.5M |
| Other current assets | — | — | — | — | $7.0K |
| Property, plant & equipment | $981.0K | $1.4M | $1.7M | $1.9M | $1.5M |
| Accounts payable | $2.3M | $2.2M | $1.9M | $3.0M | $1.6M |
| Accrued liabilities | $10.7M | $6.3M | $7.7M | $7.8M | $3.7M |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained earnings | -$297.0M | -$227.2M | -$177.6M | -$110.8M | -$47.5M |
| Accumulated other comprehensive income (loss) | $403.0K | $475.0K | $62.0K | -$3.4M | -$244.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$54.4M | -$43.1M | -$58.6M | -$51.3M | -$29.4M |
| Investing cash flow | $22.9M | $44.0M | $52.5M | -$221.0M | -$53.6M |
| Financing cash flow | $25.7M | $513.0K | $724.0K | $235.0K | $379.2M |
| Free cash flow | -$54.6M | -$43.4M | -$58.8M | -$52.2M | -$30.9M |
| Capital expenditures | $193.0K | $340.0K | $256.0K | $918.0K | $1.5M |
| Share-based compensation | $14.5M | $13.1M | $13.1M | $10.9M | $4.7M |
| Deferred income taxes | $0 | $0 | — | — | — |
| Purchases of investments | $291.8M | $230.2M | $224.7M | $313.0M | $86.3M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding DSGN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-08-13 to 2025-08-13
Recent transactions
- Most recent: William Arsani (Reporting person) — Open market sale of 345,000 shares on 2025-08-13.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| William Arsani | Reporting person | Open market sale | 2025-08-13 | 345,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-08-13 | William Arsani | Reporting person | Open market sale | 345,000 | $5.25 |
| 2025-08-13 | William Arsani | Reporting person | Open market sale | 217,627 | $5.25 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:44 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-03 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-09 | View on SEC.gov → |
| 2026-05-18 | 8-K | 2026-05-18 | View on SEC.gov → |
| 2026-04-28 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-04-28 | 8-K | 2026-04-28 | View on SEC.gov → |
Recent news
Headlines about DSGN (Design Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
DSGN Dec 2026 25.000 call (DSGN261218C00025000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
Understanding Momentum Shifts in (DSGN)
Stock Traders Daily · 2026-10-18 -
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
Seeking Alpha · 2026-10-04 -
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program
Seeking Alpha · 2026-10-02 -
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
Yahoo Finance · 2026-08-27 -
A Deeper Dive Into Design Therapeutics
Seeking Alpha · 2026-07-27 -
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Seeking Alpha · 2026-06-24 -
Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer
Yahoo Finance · 2026-06-08
No headlines in this category right now — try “All”.